SHEP Trial

Summary: Evaluated chlorthalidone with and without atenolol versus placebo in patients with hypertension. The primary endpoint of nonfatal and fatal stroke was reduced with chlorthalidone. Major adverse cardiovascular events was reduced at 5 year follow-up. Long-term follow-up showed increased risk of diabetes with chlorthalidone, but still improved clinical outcomes despite this, even in the new diabetics.

Original Publication:

JAMA. 1991 Jun 26;265(24):3255-64.

Am J Cardiol. 2005 Jan 1;95(1):29-35.

Eponym: Systolic Hypertension in the Elderly Program